Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Non-Current Debt (2021)

Supernus Pharmaceuticals (SUPN) has disclosed Non-Current Debt for 4 consecutive years, with $379.3 million as the latest value for Q4 2021.

On a quarterly basis, Non-Current Debt changed N/A to $379.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $379.3 million, a N/A change, with the full-year FY2021 number at $379.3 million, changed N/A from a year prior.
Non-Current Debt was $379.3 million for Q4 2021 at Supernus Pharmaceuticals, up from $8.0 million in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $379.3 million in Q4 2021 to a low of $379.3 million in Q4 2021.